Drugs / WT1 TCR-transduced T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01621724 | Apr 2012 → May 2018 | acute myeloid leukemia, chronic myeloid leukemia | Cell Medica Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1 TCR-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01621724 ↗ |
| Action | Deplete | “The gene transferred to the T cells enables them to make a new T cell receptor (TCR), which will allow them to attack leukaemia cells with high levels of WT1 on their surface.” NCT01621724 ↗ |
| Modality | Cell therapy | “This trial concerns a novel approach to generating leukaemia antigen-specific T cells for adoptive cellular therapy in HLA-A\*0201 patients with acute myeloid leukaemia (AML)...” NCT01621724 ↗ |
| Target | WT1 | “which allows them to recognize fragments of a protein called WT1.” NCT01621724 ↗ |